Overview of Eldex

Quick Facts

Property	Description
Active ingredient	Nimesulide
Forms	Tablet, Granules, Capsule, Topical Gel, Suppository
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose	To relieve pain, reduce fever, and diminish inflammation
Origin	Synthetic organic compound

What Type of Medicine is Eldex and What is it Made Of?

Eldex is a medicinal product based on the single active ingredient Nimesulide, which is classified pharmacologically as a Nonsteroidal Anti-inflammatory Drug (NSAID). Nimesulide is a synthetic organic compound that belongs to the sulfonanilide chemical class and acts as a preferential inhibitor of the cyclooxygenase-2 (COX-2) enzyme. This compound, distinct from older non-selective NSAIDs, is clinically recognized for its anti-inflammatory efficacy and is commonly available by prescription in many regions. Nimesulide belongs to the Anti-inflammatory and Anti-rheumatic products group, confirming its established therapeutic category.

The Pharmacological Action and General Purpose of Eldex

The general purpose of Eldex is to control the core symptoms associated with the inflammatory process, which specifically includes providing relief from pain and assisting in the reduction of fever. The action of Nimesulide involves targeted blockade of the COX-2 enzyme, which interrupts the synthesis of prostaglandins, the powerful chemical mediators responsible for pain and swelling. The active ingredient has an established role in general symptom management, with effective analgesic and antipyretic properties. The medicine provides a means to diminish general physical discomfort and moderate the body's inflammatory and febrile response.

Pharmaceutical Forms and Administration Routes

The active ingredient Nimesulide is manufactured into diverse pharmaceutical preparations, enabling multiple administration routes, a key differentiating factor for the product line. Forms include various oral options—such as tablets, dispersible tablets (DT), capsules, and granules for oral suspension—as well as non-oral options like topical gels and suppositories. This flexibility allows the medicine to be administered via oral, topical, and rectal routes, facilitating either systemic delivery for generalized effects or localized action via the topical gel to target specific areas of discomfort.

What side effects are possible with Eldex?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential side effects of systemic Eldex (Nimesulide) by frequency and organ system. The safety profile is characterized by risks common to the Nonsteroidal Anti-inflammatory Drug (NSAID) class, alongside specific concerns related to liver function.

Key Safety Characteristics and Adverse Reactions

The most significant and documented safety characteristic is the risk of Hepatobiliary disorders, including serious events such as acute liver failure, which has been reported in rare instances. This risk dictates many of the product's regulatory limitations.

Adverse reactions are also classified across other system-organ classes, including Gastrointestinal disorders (e.g., ulceration, bleeding, perforation), Cardiovascular/Vascular disorders (increased risk of thrombotic events like myocardial infarction and stroke), and Renal and urinary disorders (potential for kidney dysfunction).

Commonly reported, non-serious reactions often involve the Gastrointestinal system (such as nausea, vomiting, or diarrhea) and the Nervous System (such as headache or dizziness).

Safety Constraints and Population Restrictions

The official label imposes strict safety constraints on the systemic use of Nimesulide.

Duration: Treatment duration is strictly limited, typically to a maximum of 15 days, to limit exposure. However, the risk of serious liver injury is documented even within short courses.
Contraindications: Use is strictly contraindicated in patients with a history of severe hepatic impairment, severe renal impairment (creatinine clearance < 30 mL/min), severe heart failure, or a history of a hepatotoxic reaction to Nimesulide.
Pediatric Use: Systemic Nimesulide is contraindicated in children under 12 years of age.

These restrictions ensure the medicine is reserved for specific acute symptomatic management as defined by regulatory authorities.

Overdose and Emergency Response

Eldex Overdose and When to Seek Help

The official regulatory documentation defines the pattern of an acute Eldex (Nimesulide) overdose by describing both common clinical manifestations and the potential for rare, severe systemic outcomes.

Documented Overdose Manifestations

Acute overdose typically involves gastrointestinal disturbances, including nausea, vomiting, and epigastric pain. Central Nervous System (CNS) effects such as lethargy and drowsiness are also documented presentations.

Severe and life-threatening outcomes, though rare, are officially cited and may include gastrointestinal bleeding, acute renal failure, respiratory depression, and coma. Anaphylactoid reactions have also been noted as potential outcomes associated with NSAID overdose.

Emergency Actions and Management

Immediate medical attention must be sought upon a known or suspected acute overdose. This urgent action is required due to the potential for the severe, life-threatening complications listed in the official labeling.

Regulatory guidance states that no specific antidote is known for Nimesulide overdose. Consequently, the mandated management approach is limited to providing supportive care and managing symptoms as they arise. Clinical monitoring is required to manage potential organ system compromise.

Overdose is not expected when using the topical gel formulation due to minimal systemic absorption. Increased severity is possible in cases involving pre-existing renal or hepatic impairment.

Therapeutic Uses of Eldex

Eldex is used across therapeutic domains where short-term symptomatic assistance is needed, providing support that helps ease the overall symptom burden for patients experiencing acute episodes. It is commonly used to help with acute pain episodes, to manage symptoms associated with painful osteoarthritis, and to provide supportive relief for the physical discomfort associated with primary dysmenorrhoea.

The medication is applied across domains where additional symptomatic support is needed, particularly for symptoms related to inflammatory or irritative states. The core purpose is to address groups of symptoms that may become intense or disruptive and interfere with daily functioning. It is relevant when supportive symptom management is appropriate, especially during phases when symptoms become more noticeable.

Quick Fact: Symptom Management Focus

Property	Description
Symptom Axes Addressed	Pain, Inflammation, Fever
Clinical Contexts	Acute symptomatic episodes, post-traumatic discomfort, primary dysmenorrhoea
Patient Benefit Frame	Supports comfort and assists with maintaining functional stability
Target Conditions	Acute pain, symptomatic osteoarthritis, primary dysmenorrhoea

Regulatory References

European Medicines Agency (EMA) review

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Eldex — Official Regulatory Information

Official regulatory documents establish strict eligibility criteria for the use of Eldex (Nimesulide), primarily based on age, organ function, and pre-existing medical conditions.

Eligibility Scope	Status Based on Official Labeling
Populations for whom use is allowed	Adults and adolescents aged 12 years and older. Patients with mild to moderate renal impairment (creatinine clearance 30–80 ml/min) are eligible.
Populations for whom use is contraindicated	Children under 12 years of age; patients with hepatic impairment (of any degree); patients with severe renal impairment (creatinine clearance < 30 ml/min); patients with severe heart failure.
Physiological/Clinical States Prohibited	Use is strictly contraindicated in the third trimester of pregnancy, during breastfeeding, and in patients with a history of hepatotoxic reactions to Nimesulide. It is also prohibited in patients with active gastrointestinal ulcers, severe coagulation disorders, or fever and/or flu-like symptoms.
Eligibility-related Restrictions	The medicine is officially restricted to second-line treatment and for a maximum treatment duration of 15 days. Its use is not recommended for women who are attempting to conceive.

Connection to the overall eligibility profile: Official regulatory documents mandate that use of Eldex be confined to populations 12 years and older and impose absolute contraindications against use in patients with compromised hepatic or severe renal function. These official constraints ensure the medicine is reserved as a highly restricted treatment option.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Eldex, which contains Nimesulide, has officially documented interaction patterns that are classified by regulatory authorities. The interaction profile focuses on pharmacokinetic effects, such as the inhibition of the CYP2C9 enzyme, which can increase the plasma concentration of co-administered drugs metabolized by this pathway. Pharmacodynamic interactions involve additive effects that increase specific risks.

Official Interaction Statements

Classification	Interacting Substance/Class	Official Interaction Description
Contraindicated Combinations	Other NSAIDs, Alcohol, Potentially Hepatotoxic Substances	Explicitly prohibited due to additive risk of adverse effects, including hepatotoxicity.
Exposure Modification	Lithium, Methotrexate	Documented to reduce the clearance of these medicines, resulting in elevated serum levels and increased risk of toxicity.
Pharmacodynamic Risk	Anticoagulants (e.g., Warfarin)	Increased risk or severity of bleeding and hemorrhage when co-administered.
Reduced Efficacy	Diuretics, ACE-Inhibitors, ARBs	May reduce the antihypertensive and diuretic effects; caution is noted for elderly and volume-depleted patients due to potential renal function deterioration.

Administration Constraints

Mandatory constraints include the need for caution when administering Eldex less than 24 hours before or after Methotrexate. The regulatory profile requires close monitoring of coagulation status if Eldex is used concomitantly with anticoagulants, as defined in official product information.

Mechanism of Action

Preferential Inhibition of Prostaglandin Synthesis

The core mechanism involves the preferential inhibition of the Cyclooxygenase-2 ( COX-2) enzyme, which is responsible for synthesizing Prostaglandin E2 ( PGE2). By blocking this central step in the Arachidonic Acid Cascade both peripherally and centrally (in the hypothalamus), the drug suppresses the primary chemical signal that sensitizes pain receptors and elevates the body's thermoregulatory set-point.

Ancillary Modulation of Inflammatory Mediators

Beyond its primary action, Nimesulide engages in secondary mechanisms that modulate the local inflammatory microenvironment. It acts as a scavenger for Reactive Oxygen Species (ROS), resulting in the localized reduction of excessive mediator activity, and modulates the activity of proteolytic enzymes like Matrix Metalloproteinases (MMPs). This ancillary action limits cellular damage and supports the integrity of connective tissue structures during heightened inflammatory states.

Mechanistic Kinetics and Constraints

The mechanism involves the efficient and timely initiation of COX-2 inhibition due to its structural properties allowing efficient access to the target, which quickly initiates the mechanistic cascade of PGE2 suppression. The mechanistic effect is a rapid interference within the eicosanoid pathway. A key mechanistic constraint is the dose-dependent nature of its selectivity, as higher concentrations may lead to increased inhibition of the homeostatic COX-1 enzyme.

Dosage and Administration Information

The administration of Eldex (Nimesulide) follows defined parameters covering the appropriate route, frequency, and duration of the course. The active ingredient is used for both systemic and local administration through oral, rectal, and topical routes.

For systemic use (oral and rectal forms), the standard regimen for adults and adolescents aged 12 years and older is a single dose of 100 mg, taken twice per day. This means the maximum daily dose is 200 mg. The oral forms, such as tablets and granules, include the instruction that they are to be taken after a meal. Granules require dissolution in water immediately before ingestion.

The treatment protocol is constrained regarding duration. Systemic use is limited to the shortest possible time necessary for effect, and a single course of treatment must not exceed 15 consecutive days. This time limit establishes Eldex as a short-term medicine. The systemic medicine is recognized as a second-line treatment, meaning its use follows the consideration of other alternatives.

Official Usage Constraints
Dose and Frequency: 100 mg administered twice daily (B.I.D.).
Oral Timing: Must be taken immediately after a meal.
Duration Maximum: Must not exceed 15 consecutive days.
Dosing Adjustment: Standard dose applies to adolescents (12–18) and older adults without severe impairment.
Missed Dose: Do not take a double dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies for Eldex

Evidence for Use in Short-Term Acute Pain

The core research for Eldex was studied for short-term acute pain. This evidence is based on numerous randomized controlled trials (RCTs) and comprehensive systematic reviews that combine data from many individual studies. Research explored outcomes related to physical discomfort and the body’s response to inflammatory or irritative states. These studies were designed to monitor patterns in adult populations experiencing heightened symptom activity, such as pain following soft-tissue injuries (like sprains or strains) or dental procedures.

The studies compared the medicine against a placebo (an inactive treatment) and active comparator agents to assess changes measured during the study period. Trials were used in research exploring how symptom intensity changed over defined time intervals. Research also highlights the frequency of the measured use of concomitant medication during the study periods.

Evidence for Symptomatic Relief of Primary Dysmenorrhoea

Evidence related to Eldex was studied for primary dysmenorrhoea (menstrual pain) and comes from short-term RCTs and reviews focusing on conditions characterized by fluctuating or episodic manifestations. These studies were applied in research contexts involving fluctuating or unstable symptoms, with the aim of describing outcomes related to episodic changes during the painful phase of the menstrual cycle.

Studies report how symptoms evolved in the observed populations, and research monitored patient-reported outcomes describing perceived discomfort. Furthermore, some research examined temporary physiological imbalance by measuring changes in certain chemical mediators, such as prostaglandins, as an outcome linked to inflammatory or irritative states.

Research Gaps and Unanswered Questions

A critical aspect of the research is the follow-up duration of the key trials. For systemic forms of the medicine, the studies observing responses over defined time intervals are overwhelmingly short-term. The maximum treatment duration is often limited to 15 days, meaning long-term effects are not fully established.

Furthermore, data for certain groups remain insufficient. For instance, the research does not adequately describe patterns for specific populations, such as older adults with multiple health conditions or other defined subgroups. Comparative evidence is lacking for many newer pain management options, and subgroup findings are uncertain for patients with highly specific or complex symptom burdens.

Key Studies & References

WHO Collaborating Centre for Drug Statistics Methodology: ATC Classification, Nimesulide (M01AX17)

Frequently Asked Questions (FAQ)

Common questions about Eldex (FAQ)

Q: How does Eldex work inside the body, in simple terms?

A: Eldex contains the active ingredient Nimesulide, which is an anti-inflammatory medicine. It works by reducing the production of certain chemical messengers, called prostaglandins, that cause pain and swelling in the body. Official information describes this action as preferentially blocking the activity of an enzyme known as cyclooxygenase-2 (COX-2).

Q: How quickly can a person typically expect Eldex to start working?

A: Official information describes that the medicine begins its mechanistic action—interfering with the body's pain pathway—quickly and efficiently. However, regulatory documents do not specify a precise timeframe, such as an exact number of minutes or hours, for the onset of symptomatic relief to be observed in research settings.

Q: What is the difference between Eldex and other drugs in the same class?

A: Eldex is officially classified as a non-steroidal anti-inflammatory drug (NSAID). Its specific action is described as preferentially blocking the COX-2 enzyme. This characteristic is what distinguishes it from some older NSAIDs that inhibit both COX-1 and COX-2 enzymes.

Q: Is Eldex available as a generic version?

A: Eldex is the specific brand name for the active ingredient Nimesulide. Nimesulide is authorized for use in many countries and is also available as a non-proprietary, or generic, medicine under various names, provided it meets the same official quality and efficacy standards.

Q: What is the difference between the brand name Eldex and its generic equivalent?

A: Eldex is the specific brand name given to the medicine by the manufacturer. A generic equivalent contains the exact same active ingredient, Nimesulide, and regulatory bodies require it to work in the body in the same way as the brand-name product.

Q: What is the general duration of treatment with Eldex?

A: Treatment is restricted by official guidance to the shortest time possible required for effect. The maximum duration of a single course of systemic treatment is constrained by official documents to 15 consecutive days.

Q: Can a person stop taking Eldex if they start to feel better?

A: Official documentation states that the medicine should be used for the shortest time required. Any decision regarding cessation of use before the maximum duration is reached should be made in consultation with a healthcare provider.

Q: What if a person misses a scheduled intake of Eldex?

A: Official labeling advises that patients should not take a double dose to compensate for a missed dose. Specific guidance on how to proceed with a missed intake is not provided in the label summary and is reserved for a healthcare provider consultation.

Q: Does Eldex affect a person's ability to drive or operate machinery?

A: Official documentation advises that, as the medicine has been associated with effects like dizziness and headache, caution is noted regarding activities requiring mental alertness, such as driving or operating machinery.

Q: Does Eldex have a known effect on blood pressure?

A: Official warnings note that Eldex may reduce the blood pressure-lowering (antihypertensive) effects of certain medications, such as ACE-Inhibitors and ARBs. Regulatory documents also advise caution when the medicine is used in patients with pre-existing hypertension or heart conditions.

Q: How does Eldex interact with herbal supplements like St. John's Wort?

A: Official interaction tables list contraindications with other NSAIDs, alcohol, and potentially liver-damaging substances. While St. John's Wort is not explicitly listed, general regulatory documents advise caution regarding any concomitant use of medications or supplements. This information is reserved for a healthcare provider consultation.

Q: What happens if a person takes more Eldex than recommended?

A: In cases of acute overdose, official documents state that symptoms are typically limited to effects like nausea, drowsiness, vomiting, and pain in the upper abdomen. Official documents advise that management is typically based on providing supportive care to manage clinical symptoms, as there is no specific antidote available.

Q: Is Eldex considered a controlled substance?

A: No. Eldex contains the active ingredient Nimesulide, which is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not designated as a controlled substance by major international drug control authorities.

Q: Can Eldex affect the results of common laboratory blood tests?

A: Official warnings require the close monitoring of blood coagulation status in patients taking blood thinners due to the medicine's potential effect on platelet function. Caution is also advised regarding kidney function, which is assessed via laboratory tests, especially in elderly or volume-depleted patients.

Q: What is the risk of dependence or withdrawal symptoms associated with Eldex?

A: Official regulatory documents do not list any issues of dependence, addiction, or withdrawal symptoms as adverse reactions associated with the use of Eldex.

Q: Does Eldex cause weight gain or weight loss?

A: Weight change is not listed as a common or very common adverse reaction in official product information. However, the regulatory documentation for the drug class does note the potential for fluid retention, which may sometimes be observed with NSAIDs.

Q: Is there a patient information leaflet (PIL) available for Eldex?

A: Yes. Regulatory requirements in the countries where Eldex is authorized mandate that a Patient Information Leaflet (PIL), or a similar document like a Medication Guide, must be provided to the patient with the dispensed product.

Q: What is the most common reason people discontinue using Eldex?

A: Regulatory data emphasizes that treatment must be discontinued immediately if a patient develops fever, flu-like symptoms, or any sign of liver injury. Furthermore, commonly reported adverse reactions in clinical trials often involve gastrointestinal issues, which may also lead to discontinuation.

Q: Is Eldex used to treat any conditions other than the primary approved use?

A: Official regulatory documents clearly define and authorize Eldex only for the treatment of short-term acute pain and primary dysmenorrhoea (menstrual pain) in adolescents and adults aged 12 years and older.

Q: Are there any lifestyle changes recommended alongside taking Eldex?

A: The documentation advises that patients maintain proper hydration during the course of treatment. The official label does not specify other required lifestyle changes.

Q: Can Eldex cause changes in mood or sleep patterns?

A: Commonly reported side effects include effects on the nervous system, such as dizziness and headache. While not commonly listed, official documents for Nimesulide or related NSAIDs have noted rare occurrences of nervousness or sleep disturbances.

Q: Are there common side effects that usually decrease over time?

A: Official documentation does not provide general guidance on the typical evolution of all side effects over time. However, the risk of some serious reactions, such as severe skin issues, is noted in regulatory documents to be highest early in the course of therapy.

Q: Does Eldex require any special monitoring or regular doctor visits?

A: Regulatory guidelines advise that certain patients require close monitoring, including those with pre-existing heart or kidney conditions, those taking blood thinners (anticoagulants), or women who are attempting to conceive. Official documentation notes that in the event a patient experiences symptoms of liver injury, fever, or flu-like symptoms, the discontinuation of the medicine is required.

How should Eldex be stored and disposed of?

How to Store and Dispose of Eldex (Nimesulide)

The storage and handling of Eldex must strictly adhere to regulatory labeling to maintain product integrity and ensure safety.

Storage Requirements

Condition	Requirement
Temperature	Store at room temperature, typically between 20°C and 25°C, in a cool, dry, and well-ventilated place.
Protection	Protect the medication from heat. Keep the container tightly closed and use the original box or container.
Child Safety	The product must be stored out of reach of children and should be officially stored locked up (P405).

Disposal Instructions

Any unused or expired Eldex must be handled as pharmaceutical waste. Do not dispose of the product into drains, water courses, or onto the ground. Disposal of the contents and container must be completed by submitting them to an approved waste disposal plant or following local, regional, and national regulations for hazardous or special waste collection.

Eldex